The Global Drug Eluting Stents Market is estimated to be valued at USD 8.49 Bn in 2025 and is expected to reach USD 15.22 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032. The global drug eluting stents market has witnessed significant growth in the past few years owing to the rising prevalence of cardiovascular diseases and increasing geriatric population worldwide who are more prone to coronary heart diseases and artery blockages. Drug eluting stents are increasingly being preferred by physicians over bare metal stents due to advantages such as lower rates of restenosis. Moreover, technological advancements in design of stents and drugs coated on stent surfaces have improved clinical outcomes for patients. However, high costs of drug eluting stents compared to bare metal stents remain a major challenge for market growth.
Market Dynamics:
The global drug eluting stents market is driven by the rising geriatric population, growing burden of cardiovascular diseases, and advantages offered by drug eluting stents over bare metal stents such as lower restenosis rates. However, the high costs of drug eluting stents compared to bare metal stents can hamper the market growth. Various developments in stent technology and drug coatings are expected to present lucrative opportunities for market players. For example, bioabsorbable drug eluting stents that dissolve in the body after performing their action could witness increasing adoption. Likewise, development of stent surfaces that enhance binding of drug molecules could help reduce drug elution times and costs of treatment.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook